Skip to main content
Livermore
Livermore
ZHEN

MPM Asset Management LLC

SEC CIK
0001263048
Latest filing
Nov 14, 2025

The latest 13F from MPM Asset Management LLC covers Q3 2025 (filed Nov 14, 2025): 4 long positions worth $44.5M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Entrada Therapeutics, Inc. (TRDA) at 57.1%. Livermore has 20 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q3 2025

Share counts compared with Q2 2025: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
0
Reduced
0
Sold out
1
Est. −$1.15M

Top 5 holdings

Share of this quarter's portfolio value

  1. TRDAEntrada Therapeutics, Inc.
    57.1%$25.4MHistory
  2. DYNDyne Therapeutics, Inc.
    19.4%$8.63MHistory
  3. HOWLWerewolf Therapeutics, Inc.
    19.1%$8.49MHistory
  4. RPTXRepare Therapeutics Inc.
    4.4%$1.97MHistory

Biggest buys

New and added positions, by estimated amount bought

None this quarter.

Largest weight increases

New and added positions, by percentage points of the portfolio gained

None this quarter.

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. ADAPYAdaptimmune Therapeutics PLC
    −$1.15MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. ADAPYAdaptimmune Therapeutics PLC
    −2.66 pp2.7% → 0.0%History

Metrics

13F metrics for Q3 2025, computed only from the numbers in the filings. Definitions below.

Portfolio value
$44.5M
+$1.16M (+2.7%) vs. prior quarter
Positions
4
−1 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.0%
Q3 2025, one quarter
Average holding period
17.1 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

19 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $537.9M (Q2 2021)

Q1 2021: $517.6MQ2 2021: $537.9MQ3 2021: $431.5MQ4 2021: $462.7MQ1 2022: $292.6MQ2 2022: $237.0MQ3 2022: $262.6MQ4 2022: $239.0MQ1 2023: $240.0MQ2 2023: $203.9MQ3 2023: $186.7MQ4 2023: $203.5MQ1 2024: $245.2MQ2 2024: $182.1MQ3 2024: $145.3MQ4 2024: $124.4MQ1 2025: $69.4MQ2 2025: $43.3MQ3 2025: $44.5M
Q1 2021Q3 2025
13F filings of MPM Asset Management LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2025Nov 14, 20254$44.5MTRDADYNHOWLvs. Q2 2025SEC
Q2 2025Aug 14, 20255$43.3MTRDADYNHOWLvs. Q1 2025SEC
Q1 2025May 15, 20256$69.4MTRDAITOSDYNvs. Q4 2024SEC
Q4 2024Feb 14, 20256$124.4MTRDAITOSDYNvs. Q3 2024SEC
Q3 2024Nov 13, 20246$145.3MTRDAITOSDYNvs. Q2 2024SEC
Q2 2024Aug 14, 20246$182.1MTRDADYNITOSvs. Q1 2024SEC
Q1 2024May 15, 20246$245.2MDYNTRDAITOSvs. Q4 2023SEC
Q4 2023Feb 13, 20247$203.5MTRDADYNITOSvs. Q3 2023SEC
Q3 2023Nov 14, 20237$186.7MTRDADYNITOSvs. Q2 2023SEC
Q2 2023Sep 7, 2023Amended8$203.9MTRDADYNITOSvs. Q1 2023SEC
Q1 2023May 12, 20239$240.0MTRDADYNAmryt Pharma PLCvs. Q4 2022SEC
Q4 2022Feb 14, 20239$239.0MTRDADYNITOSvs. Q3 2022SEC
Q3 2022Nov 14, 20229$262.6MTRDADYNITOSvs. Q2 2022SEC
Q2 2022Aug 11, 202210$237.0MITOSTRDADYNvs. Q1 2022SEC
Q1 2022May 13, 202210$292.6MITOSDYNTRDAvs. Q4 2021SEC
Q4 2021Feb 11, 202210$462.7MITOSTRDADYNvs. Q3 2021SEC
Q3 2021Nov 15, 20219$431.5MITOSDYNHOWLvs. Q2 2021SEC
Q2 2021Aug 13, 20219$537.9MDYNITOSHOWLvs. Q1 2021SEC
Q1 2021May 13, 20218$517.6MITOSTCRRRPTX–SEC

13D and 13G filings

Companies where MPM Asset Management LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

MPM Asset Management LLC does not currently report owning 5% or more of any company.

Latest filings

8 filings on file made by MPM Asset Management LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by MPM Asset Management LLC
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
HOWLWerewolf Therapeutics, Inc.May 12, 20267:56 PM ETMPM BioVentures 2014, L.P.and 13 others13D/A3.80%1.83M shares−1.60 ppfrom 5.40%Below 5%May 8, 2026SEC
HOWLWerewolf Therapeutics, Inc.May 5, 20267:04 PM ETMPM BioVentures 2014, L.P.and 13 others13D/A5.40%2.61M shares−1.50 ppfrom 6.90%May 1, 2026SEC
AKTSAktis Oncology, Inc.Jan 20, 20265:44 PM ETMPM Bioventures 2018, L.P.and 12 others13D19.30%10.3M sharesNewJan 12, 2026SEC
HOWLWerewolf Therapeutics, Inc.Jan 16, 20265:36 PM ETMPM BioVentures 2014, L.P.and 13 others13D/A6.90%3.37M shares−1.30 ppfrom 8.20%Jan 14, 2026SEC
HOWLWerewolf Therapeutics, Inc.Dec 29, 20256:59 PM ETMPM BioVentures 2014, L.P.and 13 others13D/A8.20%3.98M shares−1.80 ppfrom 10.00%Dec 22, 2025SEC
HOWLWerewolf Therapeutics, Inc.Dec 3, 20257:04 PM ETMPM BioVentures 2014, L.P.and 13 others13D/A10.00%4.87M shares−1.30 ppfrom 11.30%Dec 1, 2025SEC
HOWLWerewolf Therapeutics, Inc.Nov 17, 20258:00 PM ETMPM BioVentures 2014, L.P.and 13 others13D/A11.30%5.48M shares−2.10 ppfrom 13.40%Nov 13, 2025SEC
HOWLWerewolf Therapeutics, Inc.Nov 4, 20256:33 PM ETMPM BioVentures 2014, L.P.and 13 others13D/A13.40%6.15M shares–Oct 31, 2025SEC